staging systems were applied and survival was calculated using Kaplan-Meier methods. Cox proportional hazard regression was used to determine the relationship between stage of disease and survival. Models were compared using the Akaike information criterion (AIC). RESULTS: A total of 435 patients were eligible for analysis. There was a dramatic shift in lymph node category and overall stage of disease when ICON-S and MDACC stage were applied to the JHH cohort. There was superior stratification of overall survival and progression-free survival by ICON-S stage. Both proposed models had an improved fit based on AIC scores (P<.001 for both) over the AJCC-7ed. The ICON-S staging system had the lowest AIC score, and thus a better fit within the JHH population. CONCLUSIONS: The current analysis provides external validation for both staging systems in an independent and heterogeneously treated patient population. Although the MDACC staging system is an improvement over the AJCC-7ed, the ICON-S stage provides superior stratification of overall and progression-free survival, thereby supporting its use as the updated AJCC staging system for OPC.
INTRODUCTION
Head and neck squamous cell cancer historically has been described as a homogenous disease of multiple anatomic sites that is strongly associated with tobacco and alcohol use. 1 Although the incidence of head and neck cancers overall has decreased in recent years, the incidence of oropharyngeal cancer (OPC) has increased significantly, most notably among younger men. 2, 3 This trend is driven by the relative increase in human papillomavirus (HPV)-positive OPC. HPV-positive OPC is a distinct clinical entity from HPV-negative OPC and is characterized by small primary tumors with an advanced lymph node category and overall stage of disease at the time of clinical presentation. 4 The current seventh edition staging system, as defined by the American Joint Committee on Cancer (AJCC), is based on the assumption that OPC is a homogenous disease and is agnostic to HPV tumor status, despite it being the strongest independent marker of improved prognosis. 5 Based on the current AJCC seventh edition staging system (hereafter referred to as AJCC-7ed), the majority of patients with OPC are categorized with advanced overall stage, which in classic staging systems is reserved for patients with an expected poor prognosis. Nevertheless, several investigators have demonstrated that the AJCC-7ed overall stage does not accurately inform prognosis for patients with HPV-positive OPC, both in multi-institutional series and population-based data. [6] [7] [8] Both retrospective and prospective studies have consistently demonstrated that patients with HPVpositive OPC have improved survival rates, even when controlling for tumor size and age. [6] [7] [8] [9] As a result of these observations, several novel staging systems have been proposed. In an effort to validate the initially proposed Princess Margaret staging system, 8 the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S) designed and validated a novel staging system. 10 In addition, Dahlstrom et al proposed application of the nasopharyngeal cancer lymph node staging to HPV-positive OPC (hereafter referred to as The University of Texas MD Anderson Cancer Center [MDACC] staging). 11 In anticipation of an AJCC update for OPC staging, the current analysis was designed to evaluate the prognostic ability of the 2 candidate staging systems in an independent cohort of heterogeneously treated patients with HPV-positive OPC.
MATERIALS AND METHODS

Study Population
The study protocol was approved by the Institutional Review Board at the study institution. A retrospective chart review was performed on all patients with a diagnosis of HPV-positive oropharyngeal squamous cell carcinoma who were evaluated at Johns Hopkins Hospital (JHH) between January 1, 2005 and December 31, 2015. The cohort hereafter will be referred to as the "JHH cohort." Demographic and clinical characteristics of interest were abstracted retrospectively. The lymph node category was confirmed by computed tomography or magnetic resonance imaging. Institutional HPV tumor testing was comprised of in situ hybridization in addition to p16 immunohistochemistry. HPV in situ hybridization results, as clinically available, were used to determine tumor HPV status. Patients with equivocal HPV testing or incomplete clinical information were ineligible for analysis. Disease status and vital status also were determined. 
Staging
Clinical tumor (T), lymph node (N), and distant metastasis (M) classifications as defined by the AJCC-7ed system were abstracted for each patient. 12 TNM categories for the ICON-S and MDACC models then were applied to the JHH cohort. T classification is consistent for the AJCC-7ed, ICON-S, and MDACC staging systems. However, lymph node classification differs across these models. The lymph node classification for each model is summarized in Figure 1 . Briefly, the AJCC-7ed uses a combination of the number of lymph nodes, size, and laterality to discern between N1, N2, and N3 disease. ICON-S simply uses laterality and size to differentiate N1 versus N2 versus N3 disease. In ICON-S, ipsilateral lymph nodes of any number and measuring <6 cm are classified as N1 disease. Bilateral or contralateral lymph node disease measuring <6 cm is considered to be N2 disease. Consistent with the AJCC-7ed, any lymph node measuring >6 cm is N3 disease in ICON-S. The MDACC staging system applied nasopharyngeal lymph node category and therefore used laterality and location with respect to the supraclavicular fossa. The N classification for each case was reclassified into ICON-S and MDACC using these definitions. Lymph nodes were classified as above the supraclavicular fossa (N2) or below (N3) according to radiographic review. M classification is consistent throughout all 3 models. Finally, an overall stage for each staging system then was assigned for each patient.
Statistical Analysis
Descriptive statistics were used to summarize patient characteristics. Two-tailed Student t and chi-square tests were used to compare patient characteristics. Overall survival (OS) and progression-free survival (PFS) were determined using the Kaplan-Meier method. The log-rank test was used to determine differences in survival. OS was defined as the time from diagnosis to death from any cause. Censoring occurred when a patient was lost to follow-up. PFS was defined as the time from diagnosis to the first clinically detectable disease recurrence or death from any cause. Censoring occurred when a patient was lost to follow-up. Cox proportional hazards regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (95% CIs) to determine an association between clinical variables of interest and survival. Within the AJCC-7ed model, there were no deaths in stage I. Therefore, stages I and II were combined to serve as the reference group. The Akaike information criterion (AIC) was used to compare the fit of our survival data to the 3 models. The AIC score is a quantitative measurement that considers model fit and model complexity. It is used to determine model fitness, whereby the optimal model is associated with a lower score. 13 Bootstrapping was used to generate 95% CIs for the AIC. The iteration was repeated 1000 times, excluding 15 random samples from the data set at each iteration. R statistical software (version 3.0.2; The R Foundation, Vienna, Austria) was used for all statistical analyses. Graphs were generated using Prism (GraphPad Software, La Jolla, Calif).
RESULTS
The study population was comprised of 435 patients with HPV-positive OPC. Demographic and clinical data for the study population are summarized in Table 1 . The mean age at the time of diagnosis was 58 years (standard deviation, 9.4 years). The majority of patients were male (379 patients; 87%) or white (388 patients; 89%). Few patients were current smokers (42 patients; 10%) or heavy drinkers (56 patients; 13%), although many were former smokers (194 patients; 45%). The majority of tumors were located in the palatine tonsil (223 tumors; 51%) or base of the tongue (203 tumors; 47%). As expected, tumor burden was low; 164 tumors (38%) were classified as T1 and 171 (39%) were classified as T2. By contrast, lymph node disease was common, as 71% of patients (307 patients) were classified as having N2 disease at the time of diagnosis. Thus, the vast majority of patients (403 patients; 93%) were of an advanced overall stage (stage III/IV) according to AJCC-7ed schema. There were important differences between the JHH study population and the published study populations of ICON-S and MDACC (see Supporting Information Table  1 ). Compared with the ICON-S cohort, there was no difference in distribution by sex (P 5 .075) or lymph node category (P 5 .68). It is important to note that the JHH cohort had a higher percentage of T1 tumors (38% vs 26%; P<.001) and patients treated with primary surgery (38% vs 2%; P<.001) compared with ICON-S. In comparison with the MDACC cohort, the JHH cohort was similar in terms of age (P 5 .60), sex (P 5 .96), and lymph node classification (P 5 .31). However, the JHH cohort had a higher percentage of patients with smaller tumors (T1: 38% vs 32% [P 5 .014]) than the MDACC cohort. Furthermore, there was a higher percentage of patients treated with primary surgery (38% vs 2%; P<.001).
Univariate Survival Analysis
The median follow-up was 36 months (range, 3-134 months; interquartile range, 19-59 months). A survival analysis was performed to determine whether staging and other factors were associated with OS and PFS.
For the JHH cohort, increasing year of age (HR, 1.04; P 5 .009) was found to be associated with a significantly increased risk of death. A history of smoking, defined as former or current smoking status, was not found to be associated with risk of death in univariate analysis (HR, 1.2; P 5 .58). It is interesting to note that primary surgical treatment was found to be significantly associated with a lower risk of death (HR, 0.33; P 5 .012).
Similar trends were observed with regard to PFS. Increasing year of age (HR, 1.04; P<.001) was associated with an increased risk of disease progression. Primary surgical treatment was found to be associated with a lower risk of disease progression (HR, 0.38; P<.001).
Survival by the AJCC-7ed Staging System
To determine the usefulness of the current AJCC-7ed staging system for prognostication, Kaplan-Meier survival analysis was conducted. A consistent reduction in OS across the disease stages was not observed (Fig. 2A ). There were no deaths noted among patients with overall stage I disease (11 patients). The 5-year OS rates for patients with stages II, III, and IV disease were 90%, 97.3%, and 85.6%, respectively (log-rank P 5 .04) ( Table 2) . Indeed, in univariate analysis, there was no difference in risk of death observed when comparing overall stage III disease with stages I/II disease (HR, 0.97; P 5 .98). There also was no difference noted with regard to the risk of death when comparing overall stage IV disease with overall stages I/II disease (HR, 3.50; P 5 .22).
After
.22] using stage I/II as the reference). Similarly, the 5-year PFS rate was not found to be statistically different across the stages of disease (log-rank P 5 .09) (Fig. 2B) (Table 2) .
ICON-S Staging System Applied to the JHH Cohort
The distribution of lymph node classifications significantly changed when the ICON-S classification was applied to the JHH cohort (P<.001) (Fig. 3A) . The observed shift in lymph node classification can be attributed to the 253 patients with N2a or N2b disease under the AJCC-7ed system who were recategorized as having N1 disease using the ICON-S system. Furthermore, the majority of patients were reclassified as having overall stage I disease (281 patients; 65%), whereas only 18% of patients (77 patients) were classified with advanced stage disease (stage III/IV) at the time of diagnosis. This represents a significant difference from the distribution in the AJCC-7ed stage, in which the majority of patients were diagnosed with advanced stage (343 patients; 93.7%) (P<.001) (Fig. 3B) .
There was a significant difference in OS across the ICON-S stages (log-rank P<.001) (Fig. 2A) . In contrast to the similarity in OS observed across early stages in the AJCC-7ed staging system, application of the ICON-S stage resulted in a significant decrease in OS across increasing stages of disease ( 
MDACC Staging System Applied to the JHH Cohort
When the MDACC staging system was applied to the JHH patient population, a distinct shift in lymph node classification was observed. Of the patients with N2a or N2b disease in the AJJC-7ed system, 240 were reclassified as having N1 disease (P<.001) (Fig. 3A) . In addition, 21 patients were reclassified as having N3 disease given the presence of supraclavicular lymph node metastases. When the overall stage was applied (Fig. 3B) Table 2) , although the risk of death was similar for patients with stages II and III disease (P 5 .73). Increasing age (aHR, 1.05; P 5 .007) also was found to be significantly associated with a higher risk of death in multivariate analysis. Primary surgical treatment was not found to be associated with a lower risk of death after accounting for other factors (aHR, 0.58; P 5 .26).
Significant decreases were observed for 5-year PFS across disease stages (stage IA: 87.7%; stage IB: 80.1%; stage II: 63.1%; stage III: 57.8%; and stage IV: 0%; logrank P<.001) (Fig. 2B) (Table 2) . However, the risk of disease progression for patients with stages II and III disease was statistically similar (P 5 .53). surgical treatment. It is important to note that in both the ICON-S and MDACC cohorts, only 2% of patients underwent primary surgical treatment. 10, 11 Despite the inclusion of treatment modality in their final survival analysis, it was unclear whether there was sufficient power to discern differences in risk based on primary treatment given that the vast majority of patients were treated with primary radiation-based therapy. Indeed, treatment modality did not appear to significantly contribute to OS or PFS within the ICON-S or MDACC model according to our analysis. The results of the current study demonstrate that the ICON-S staging system continued to risk stratify in a more heterogeneous cohort of patients. By contrast, the MDACC staging system did not stratify survival well when applied to this patient population.
When comparing the fit of these 2 staging systems, both the ICON-S and MDACC models had a lower AIC, and thus a better fit, when compared with the AJCC-7ed system. However, ICON-S had the lowest AIC and provided better hazard discrimination and a more consistent decrease in survival across the stages of disease when compared with the MDACC model. We thus concluded that the ICON-S staging system offers a significant improvement in prognostication over the current AJCC-7ed guidelines.
A potential bias in the current study is the lack of mature follow-up for the most recently diagnosed patients. However, our follow-up range is similar to that reported in the MDACC study, 11 and patients without mature follow-up became censored in our survival analysis. This analysis also had the biases inherent to retrospective studies. Although the cohort was relatively small (435 patients), it is important to still discern survival differences in smaller populations than the previously published development cohorts. It is important to note that although cumulative pack-years is a recognized risk factor for death, such data were unavailable due to the retrospective nature of the current analysis.
The data from the current study support prior analyses that demonstrated that the AJCC-7ed staging model is inadequate for predicting survival among patients with HPV-positive OPC. Furthermore, we demonstrated the shifts in lymph node category and overall staging that occur with the proposed models. Both the ICON-S and MDACC staging systems stratify patients according to OS and PFS. However, in the JHH population, only the ICON-S staging system provides a consistent decrease in OS and PFS across the stages of disease. The results of the current study validate the ICON-S staging system for HPV-positive OPC in an independent cohort of heterogeneously treated patients with important clinicodemographic differences, thereby supporting its use in the updated AJCC staging for OPC.
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